27
Participants
Start Date
January 22, 2016
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
Pembrolizumab
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Commack, Commack
Cleveland Clinic, Cleveland
Md Anderson Cancer Center, Houston
University of Utah, Salt Lake City
University of California, Los Angeles, Los Angeles
University of California San Francisco, San Francisco
University of Miami, Miami
Memorial Sloan Kettering Cancer Center, Basking Ridge
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Memorial Sloan Kettering Monmouth, Middletown
Memorial Sloan Kettering Bergen, Montvale
Merck Sharp & Dohme LLC
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Dana-Farber Cancer Institute
OTHER
University of California, San Francisco
OTHER
Huntsman Cancer Institute/ University of Utah
UNKNOWN
University of California, Los Angeles
OTHER
University of Miami
OTHER
Memorial Sloan Kettering Cancer Center
OTHER